Israel’s leading tech institution, the Technion, has been rated the number one institute in leading European machine-learning research in a rating by CSRankings.

Israel’s leading tech institution, the Technion, has been rated the number one institute leading machine-learning research in Europe in a rating by CSRankings. The rating is based on data gathered between 2016 and 2021.

The Technion also placed 15th globally in artificial intelligence research and 11th in machine learning.

Some 46 people are researching AI at the Technion and over 100 are conducting research in the fields of industrial robotics, cybersecurity and smart vehicles. Some 42 of these researchers have done work that was published up to 30 times at computer science conferences, according to the rankings.

The Technion’s Machine Learning and Intelligent Systems research center has led groundbreaking research in AI both in Israel and worldwide, collaborating with other institutions involved in research in the field such as Carnegie Mellon University and American software company PTC, and connecting researchers with the industry.

The Computer Science Faculty building at Technion University in Haifa, Israel (credit: BENY SHLEVICH/WIKIMEDIA COMMONS)

“We are very proud of the recognition The Technion has received in its contribution to artificial intelligence – especially as it continues to make deep and personal connections with others in the field and a significant impact on what we can hope to expect from it in the future,” the Director of Technion UK, Alan Aziz, said.

The Technion – Israel Institute of Technology in Haifa has attained global prestige for work in numerous scientific fields, including life sciences, biotechnology, stem-cell research, sustainable energy, water management, materials engineering and aerospace and information technology. Over 13,000 students currently attend the university.

Dr. Martin Ellis, Chairman of the Israel Society of Hematology and Transfusion Medicine, spoke to The Jerusalem Post about two newer treatments for the main types of blood cancer.

Although only around five out of every 100,000 people suffer from blood cancer, the disease is among the most serious and deadly.

An estimated 68,000 people die from blood cancer each year in the United States alone, according to the Leukemia Research Foundation. The statistics in Israel are unknown.

But new and innovative treatments are being explored, according to Dr. Martin Ellis, Chairman of the Israel Society of Hematology and Transfusion Medicine.

He spoke to The Jerusalem Post about two newer treatments for the main types of blood cancers, leukemia, lymphoma and myeloma, in recognition of Blood Cancer Awareness Month.

For starters, CAR-T cells are currently playing a key role in treating people with blood cancer.

“We remove the T-cells from the patient and send them to the lab, where they get engineered using genetic engineering technology to identify specific molecules on the surface of the patient’s cancer,” Ellis, who is also head of the Hematology Department at Meir Medical Center in Kfar Saba, explained. “These engineered CAR-T cells are re-infused into the body intravenously. Then, the modified cells seek and destroy the malignant cells in the body.”

A model of the protein (the blue ribbon) and the DNA (the spheres) is binds (credit: WEIZMANN INSTITUTE OF SCIENCE)

He said the treatment is generally used on people with lymphoma and multiple myeloma, and specifically those who had prior treatments that did not work or had been in remission and the cancer came back.

“CAR-T can achieve a remission in the region of 60% to 70% of patients,” Ellis said. “And it appears that around 30% are actually cured. This is an unprecedented rate of success in the realm of cancer therapy.”

Doctors are already using the patient’s own immune system to attack his or her tumors, but on the horizon will be the use of CRISPR technology, which is “basically modifying as you would with an eraser and pencil the sequence of DNA in tumor cells and replacing the abnormal part of the DNA with normal DNA,” he explained.

So far, this has been done successfully in benign hematology, but not in malignant hematology. It is “trickier when it comes to cancer cells because the abnormalities are many and vary from cell to cell,” Ellis said. But he added that he expects doctors and scientists to get there soon.

Israel has been at the forefront of the next generation of blood cancer treatments. The CAR-T technology was first conceived and developed in the Weizmann Institute of Science by renowned immunologist Zelig Eshhar.

Moreover, Israeli Nobel Prize winning scientists Aaron Ciechanover and Avram Hershko from the Technion discovered a pathway responsible for the degradation of proteins, which was crucial to the creation of proteasome inhibitors that slow the degradation of proteins and hence inhibit the progression of cancer. Specifically, one of the most successful drugs used to treat multiple myeloma, Bortezomib, is based on this discovery.

“When it comes to treating blood cancers, the Israeli contribution has been significant and, as usual, out of proportion to our population and size,” Ellis said. 

For the first time, Technion scientists succeeded in constructing a network of major and small blood arteries, crucial for giving blood to implanted tissue

Researchers lead by Technion Professor Shulamit Levenberg, who specialises in tissue engineering, have succeeded in establishing a hierarchical blood artery network, crucial for giving blood to implanted tissue. In the research published in Advanced Materials, Dr. Ariel Alejandro Szklanny employed 3D printing for constructing huge and small blood arteries to form for the first time a system that comprised a functioning combination of both. The breakthrough took accomplished in Prof. Levenberg’s Stem Cell and Tissue Engineering Laboratory in the Technion’s Faculty of Biomedical Engineering.

The heart pumps blood into the aorta, which branches out into progressively smaller blood arteries, bringing oxygen and nutrients to all the tissues and organs. Transplanted tissues, as well as tissues created for transplantation, require similar blood vascular support.

Printing Blood Vessel Networks for Implantation

Previous experiments with synthetic tissue containing hierarchical vessel networks have involved an intermediary step of transplanting first into a healthy limb, enabling it to be infiltrated by the host’s blood vessels, and then transferring the structure into the damaged location.

Notably, whereas prior studies employed animal collagen to create the scaffolds, the Israeli company CollPlant modified tobacco plants to make human collagen, which was successfully used for 3D bioprinting the vascularized tissue structures.

This study is a significant step forward in the direction of individualized medicine. Large blood vessels with the precise shape required can be manufactured and inserted alongside the tissue to be implanted. This tissue can be created using the patient’s own cells, hence avoiding the possibility of rejection.

Notably, whereas prior studies employed animal collagen to create the scaffolds, the Israeli company CollPlant modified tobacco plants to make human collagen, which was successfully used for 3D bioprinting the vascularized tissue structures.

This study is a significant step forward in the direction of individualized medicine. Large blood vessels with the precise shape required can be manufactured and inserted alongside the tissue to be implanted. This tissue can be created using the patient’s own cells, hence avoiding the possibility of rejection.

SOURCE

The future of personalised medicine: Technion team built blood tree from scratch

Currently, transplanted grafts need to be implanted into a healthy part of the body so that the patient can generate new blood vessels to support it.

Engineered blood vessels in Technion study. Vascular structures in the scaffold lumen (brown) communicate with vessels located in the surrounding hydrogel (green).
(photo credit: Courtesy)

Skin flaps, bone grafts, implanted tissue – recent advancements in medicine have changed the face of surgery in terms of autologous – meaning self – transplantations.

While extensive damage to organs once meant a nearly sure amputation or need for an external transplant, today’s science focuses on harvesting cells and tissue from a person’s own body to complete the injured pieces of the puzzle, using grafts and flaps to repair skin, vessels, tubes and bones.

Yet, ask any surgeon attempting to insert a flap and they would tell you that the most important – and restrictive – component of a graft’s success is ample blood supply.

A team of researchers at the Technion recently found a way to meet this need. For the first time, these scientists succeeded in 3D printing a network of big and small blood vessels that could provide blood to implanted tissues just like the human body.

Up until now, medicine hasn’t been able to mimic the body’s ability to create a suitable hierarchy in the blood vessel tree. In our bodies, the heart pumps blood into a large tube called the aorta, which measures roughly 2-3 cm in diameter. The blood vessels then branch off into smaller and smaller tubes that are appropriate to each organ’s need and capacity, until they reach minuscule arterioles of only 5 to 10 micrometers.

HUMAN BODY circulatory system showing the heart and blood vessels (credit: FLICKR)

Dr. Ariel Alejandro Szklanny of the Technion team, led by Professor Shulamit Levenberg, a specialist in tissue engineering, found a way to use 3D printing to form a system containing a functional combination of both the large and small vessels.

The new breakthrough may allow a tissue flap to be created in a lab already connected to a blood network suited to its size and function.

Currently, transplanted grafts need to be implanted into a healthy part of the body so that the patient can generate new blood vessels to support it; then, the graft is relocated to an affected area as healthy tissue.

The new technique could potentially eradicate this intermediate step, drastically improving recovery times and cutting down on the number of procedures a patient would need to undergo.

In his recently published study in Advanced Materials, Dr. Szklanny described how he created a polymeric scaffold filled with small holes, mimicking the large blood vessels of the body. These holes allowed the connection of smaller vessels to join into the engineered large vessels. With collagen bio-ink, the team then printed and assembled a complex network around and within the main scaffold, later covering it with endothelial (human blood vessel lining) cells. A week later, the incubated artificial apparatus joined with the cells to create a hierarchical structure just like the human blood vessel tree. 

While previous studies in this field used animal-borne collagen, the Technion team used engineered tobacco plants created by the Israeli company CollPlant.

The mesh was transplanted into a study rat and attached to the main artery in its leg. The blood through the artery spread through the network exactly as it would within the body, carrying oxygen and nutrients to the distant parts of the implanted tissue, and without any leaks.

This achievement is an important tool in the world of personalized medicine and could be a huge leap forward in tissue engineering and treatment.

Israel’s Itamar Medical, a medtech firm that produces devices to aid the diagnosis of sleep disorders, announced on Monday that it has signed a deal to be acquired by Zoll Medical for a total value of about $538 million.

Zoll Medical will acquire all outstanding shares of Itamar Medical for $31 per ADS (American Depository Share,) or $1.03 (equivalent to approximately NIS 3.31) per ordinary share, in cash. The offer of $31 per ADS in cash represents a 50.2 percent premium over the price of Itamar Medical’s ADS on Nasdaq this past Friday.

Since news of the acquisition broke, Itamar Medical’s stockhas has surged, spiking more than 43 percent in pre-market session.

Zoll Medical is an international medical devices manufacturer that develops products and software solutions focused on improving outcomes with novel resuscitation and acute critical care.

US sleep apnea diagnostic and treatment firm Lofta partnered with Itamar Medical to integrate the company’s diagnostic tool into its process. 

Founded in 1997 by Giora Yaron, now , Itamar Medical is focused on the development and commercialization of non-invasive medical devices and solutions to aid the diagnostics of respiratory sleep disorders.

Itamar Medical developed the WatchPAT Home Sleep Apnea Device, a sleep diagnosis program for patients and healthcare professionals. The company’s WatchPAT One device is cleared by the FDA and is recognized as a safe and effective method for home-based testing for sleep apnea.

 “The integration of Itamar’s WatchPAT technology and Digital Health solution for sleep apnea with Zoll Medical’s commercial footprint will accelerate our mission of advancing home sleep medicine to benefit the population of undiagnosed and untreated patients,” said Gilad Glick, president and Chief Executive Officer of Itamar Medical.

“Zoll Medical is committed to improving outcomes for underserved patients suffering from serious cardiopulmonary conditions,” said Jon Rennert, CEO of Zoll Medical. “It is currently estimated that 60% of cardiovascular patients suffer from some form of sleep apnea, and the majority of these patients go undiagnosed. The combination of ZOLL Medical and Itamar Medical will help more patients receive diagnosis and treatment for sleep-disordered breathing. We look forward to helping strengthen the collaboration between the worlds of cardiology and sleep medicine.”

Zoll Medical expects the acquisition to close by the end of 2021, subject to approval by the shareholders of Itamar Medical, regulatory approvals, and other customary closing conditions.

Sleep diagnostics at home

While most of Itamar Medical’s diagnostic devices were used by cardiologists and other specialists in sleep laboratories, the onset of the COVID-19 pandemic meant that the company’s emphasis shifted to home diagnostic kits. Toward the start of the pandemic when little was known about who it predominantly affected and why, patients suffering from all kinds of ailments – including sleep apnea – would be reticent about going to hospitals to fulfil appointments. Meanwhile, the stresses of working from home, potential loss of income and the need to homeschool children, likely increased the onset of sleep apnea, requiring an at-home solution.

The company’s revolutionary WatchPAT system, an easy-to-use, accurate, Home Sleep Apnea Test (HSAT) and sleep study device continues to remain reliable for this very reason. The WatchPAT was designed with patient use in mind for “in-home” sleep apnea testing in the comfort of one’s own bedroom, the company has said. This environment is more representative of one’s personal sleep habits.

Screenshot of the WatchPAT One, Itamar Medical’s disposable home sleep apnea test product.

The WatchPAT system attaches to a user’s index finger, chest and wrist to record vital measurements that are used to identify events of sleep apnea. It measures peripheral arterial (PAT) signal, heart rate, oximetry (a non-invasive way of monitoring a person’s oxygen saturation) , actigraphy (a non-invasive method of monitoring human rest/activity cycles), body position, snoring and chest motion.

The device is connected to the smartphone. Prior to sleep, patients can pair the wearable device to their phone. A smartphone app transmits the WatchPAT One’s data from seven channels to the cloud. Once the study is compelted, data can be sent to a clinician for review.

One of the most unique aspects of the device is that it is disposable. That means once a patient has slept with the device, they can dispose of it rather than needing to send it back or manually download data.

In 2016, Itamar Medical received FDA clearance to expand the medical indication of WatchPAT for sleep apnea diagnosis. Under that approval, the use of WatchPAT in the USA was permitted from the age of 12, expanding the previous indication for ages 17 and older.

At the time – and the problem could be increasingly acute now – the incidence of sleep apnea in adolescents reached alarming rates. It was attributed, among other comorbidities such as the increase of obesity in this age group. Additional factors could also include Attention Deficit Hyperactivity Disorder (ADHD), in which patients would likely not receive the appropriate medical care as long as the underlying sleep apnea remained undiagnosed and untreated.

The sleep apnea market is a growing one, predicted to expand to some $9.9 billion by 2026. Indeed, the highest compound annual growth rate is expected to occur in the home-based individuals’ segment, in part driven by an increasing personal awareness of the health benefits associated with resolving sleep apnea issues.

Study of 11,000 infected adults during the Delta wave in Israel sees vaccine’s protection disappearing at six months and restored by third dose.

An Israeli study has found that the two-dose Pfizer/BioNTech vaccine against Covid-19 is initially effective in reducing the viral load of breakthrough infections — even with the Delta variant of the SARS-CoV-2 coronavirus.

The lower the viral load, the lower the chance of transmitting the virus and developing symptoms.

But after analyzing viral loads of over 11,000 infected adults during the summer Delta-dominant wave in Israel, the researchers saw the vaccine’s protection starts declining two months after the second dose and disappears by about six months.

“Encouragingly, we find that this diminishing vaccine effectiveness on breakthrough infection viral loads is restored following the booster vaccine,” the researchers write.

In fact, the third vaccination caused a more than four-fold reduction in viral loads.

The study results, posted September 1 on the medRxiv website prior to peer review, was carried out by a multidisciplinary team of researchers from the Technion-Israel Institute of Technology, Tel Aviv University and Maccabi Health Services.

The findings seem to support Israel’s unprecedented decision, in July, to begin offering booster shots to citizens at least five months past their second vaccine dose.

As of now, more than 3 million Israelis have gotten that third shot. A recent Israeli study in the New England Journal of Medicine confirms the effectiveness of the booster at preventing both infection and severe illness.

How long the booster’s protection remains effective is a question that can be answered only by further research.

The study was supported by a grant from the Israel Science Foundation as part of the KillCorona-Curbing Coronavirus Research Program.

SOURCE

COVID Booster Shot Reduces Viral Load, Limits Transmission, Israeli Study Finds

The study, which has yet to be peer-reviewed, analyzed samples from 11,000 people infected with the COVID delta variant in Israel and found booster shots reduced viral loads by a factor of four

A vaccination center in Jerusalem, last monthCredit: Emil Salman

A booster shot of Pfizer’s coronavirus vaccine significantly reduces viral load in patients infected with the delta variant, and therefore reduces the chances of transmission, a new Israeli study has found.

The study was conducted jointly by the Technion – Israel Institute of Technology and KSM – the Maccabi Research and Innovation Center. It was published on the MedRxiv website, which is for papers that haven’t yet been published in a scientific journal.

The researchers concluded that about six months after someone receives the second dose of the vaccine, its effectiveness at reducing viral load dissipates. But a third dose slashes viral loads by a factor of four, thereby restoring the vaccine’s effectiveness to what it was shortly after the second dose was administered.

The researchers analyzed 11,000 PCR swab tests conducted by the Maccabi health maintenance organization on patients who had been infected with the delta variant. These patients were divided into three groups – people who were never vaccinated, people who were infected within six months of getting the second dose and people who were infected after getting the booster shot.

“What we discovered is that the vaccine’s effectiveness with respect to viral load gradually wanes over time, until after six months, [viral load] reaches a high level, similar to that of an unvaccinated person,” said Matan Levine-Tiefenbrun, a doctoral student at Tel Aviv University who is also affiliated with the Technion and was the lead researcher. “Nevertheless, we discovered that the booster shot brings the viral load back down by a factor of four, to what it was before.”

A medical worker prepares a coronavirus vaccine dose in Jerusalem, last month.Credit: Ohad Zwigenberg

The PCR test enables researchers to assess the size of the viral load based on how many times sequences of the virus’ DNA needed to be replicated to produce a result. The greater the number of replications required, the lower the initial viral load was. Analyzing large numbers of such tests enables researchers to identify broad trends – in this case, the relationship between and how long it has been since the patient’s last vaccine dose.

Viral load is a significant factor in both the likelihood of developing symptomatic illness and the likelihood of transmission, since someone who is coughing and sneezing will spread the virus more than an asymptomatic patient would.

The study found that people infected less than two months after their second dose had lower viral loads than unvaccinated people. Consequently, they also had milder symptoms and were less infectious.

But after those first two months, the researchers said, immune protection gradually begins waning and viral loads rise. This process peaks after about six months.

Aside from Levine-Tiefenbrun, the other researchers were Prof. Roy Kishony and Dr. Idan Yellin, both of the Techion, and a group of researchers from KSM led by Dr. Tal Patalon.

In March, this same group published an article in the journal Nature Medicine showing that Pfizer’s coronavirus vaccine starts significantly reducing viral load as early as 12 days after the first dose. But that study involved the alpha variant, also known as the U.K. variant, rather than delta.

“We’re seeing that the vaccines are also effective in the fourth wave, against the delta variant,” Kishony said. “The effectiveness seems very similar to what it was against the British variant after receipt of the first two doses.”

However, he added, the results of the earlier study can’t be compared directly to the results of the new study, “because the British variant has been pushed aside and disappeared.”

The new study bolsters the data from another Israeli study, this one peer-reviewed, that was published last week in the New England Journal of Medicine, and which FDA experts made use of in discussing whether to recommend booster shots in the United States. That study found that the vaccine’s effectiveness in preventing transmission declines significantly after six months, but even then, vaccinated people are roughly 50 percent less likely to infect others than unvaccinated people.

After the booster, however, Pfizer’s vaccine is 95 percent effective in preventing transmission, that study said.

The risk of severe disease dropped by factor of almost 20 in people over 60—but some dispute the benefits of offering an additional dose

Older Israelis who have received a third dose of a COVID-19 vaccine are much less likely to test positive for SARS-CoV-2 or to develop severe COVID-19 than are those who have had only two jabs, according to a highly anticipated study published on 15 September.

The standard regimen for messenger RNA-based COVID-19 vaccines is two doses, but some governments, including Israel’s, have started administering third ‘booster’ shots. The latest study evaluated 1.1 million Israelis over the age of 60 who had received their first two doses at least five months earlier. Twelve or more days after receiving a third jab, participants were about 19.5 times less likely to have severe COVID-19 than were people in the same age group who had received only two jabs and were studied during a similar time period.

“It’s a very strong result,” says Susan Ellenberg, a biostatistician at the University of Pennsylvania in Philadelphia, who adds that the data might be the most robust she has seen in favour of boosters. But potential biases in the data leave some scientists unconvinced that boosters are necessary for all populations—and the data do not dispel concerns about vaccine equity when billions of people are still waiting for their first jab.

Israel, which got an early start on vaccinating its population, began offering third doses of the Pfizer–BioNTech vaccine in July, to people aged 60 and over. The latest analysis links the third jab not only with a significant reduction in severe COVID-19, but also with an 11.3-fold reduction in SARS-CoV-2 infections.

But Ellie Murray, an epidemiologist at Boston University in Massachusetts, cautions that observational studies such as this analysis can contain biases that are difficult to identify and account for. For example, people who sign up to get a booster might have a different risk of COVID-19, or behave differently, from people who do not get a third jab.

Ellenberg says that the authors try to address some of these potential biases. Even if not all biases have been eliminated, she says, the magnitude of the effect suggests that the booster offers some protection, at least in the short term. The authors of the study could not be reached before publication.

GLOBAL RAMIFICATIONS

The findings come as a slew of wealthier nations consider offering booster shots. An advisory committee of the US Food and Drug Administration (FDA) will discuss Pfizer’s application to supply boosters in the United States on 17 September. One of the authors of the Israeli study is slated to present data to the committee.

Murray argues that the potential biases in the data, and insufficient evidence for waning immunity after vaccination, mean that the latest findings don’t indicate a “strong need” for boosters. “From a public-health perspective, it’s way, way more impactful to get more people vaccinated than it is to boost the vaccine effectiveness by a few percentage points in those who have already gotten the vaccine,” she says.

Murray is not alone in finding the Israeli results insufficient to justify boosters. A review published on 13 September by a team that includes two high-ranking FDA scientists cites a preprint of the study and notes that the short-term protective effect documented in Israel “would not necessarily imply worthwhile long-term benefit”.

Dvir Aran, a biomedical data scientist at Technion—Israel Institute of Technology in Haifa, says that Israel has deployed boosters to stop transmission in younger people and to prevent severe disease and deaths in older people.

“Is it the best way? Whether a two-week lockdown would have given a similar result, I can’t answer that question,” he says. “But it’s an interesting approach, trying to stop an outbreak like this with vaccinations.”

SOURCE

Study: COVID booster recipients 20 times more protected against serious illness

As US officials set to mull okaying Pfizer’s 3rd dose, data from a million Israelis shows it boosts protection from infection tenfold compared with eligible people who got 2 shots

A syringe is prepared with the Pfizer COVID-19 vaccine at a clinic at the Reading Area Community College in Reading, Pennsylvania, September 14, 2021. (AP/ Matt Rourke)

A new study conducted in Israel shows that individuals given a third COVID-19 vaccine dose are nearly twenty times more protected against serious illness and more than ten times more protected against infection, compared with those who received their second dose at least five months previously.

The research, published on Wednesday by The New England Journal of Medicine, showed that 12 days after receiving a booster shot of a Pfizer-BioNTech COVID-19 vaccine, the chance of infection was 11.3 times less than among those eligible for a third shot but didn’t get one.

And the chance of suffering serious illness as a result of COVID-19 among those who had received a booster shot was 19.5 times less, the research said.

The study was conducted by researchers from the Weizmann Institute of Science, the Ministry of Health, the Technion, the Hebrew University, Sheba Medical Center, and the KI Institute.

Even with a more conservative analysis, which attempted to control possible behavioral differences between the two groups, the infection rate was at least 5 times lower in the group that had received the booster shot, the Health Ministry said in a statement.

The research includes data from more than 1 million Israelis. Among those who hadn’t received a booster shot despite being eligible, there were 4,439 confirmed infections, including 294 serious patients. Among those who received the booster at least 12 days previously, there were 934 infections including 29 serious cases.

An Israeli woman receives a third dose of the COVID-19 vaccine at a Clalit clinic on September 1, 2021 in Jerusalem. (Olivier Fitoussi/Flash90)

The Israeli data could not say how long the boosted protection lasts.

But a separate study conducted at Sheba Medical Center in Ramat Gan, outside Tel Aviv, has stoked optimism as to the amount of time for which the booster shot retains its protection.

The study found that the antibody levels a week after the third COVID-19 vaccine dose was administered to its staff were ten times higher than their levels a week after the second dose was administered.

Israel — the first country to officially offer a third dose — began its COVID-19 booster campaign on August 1, initially rolling it out to those over the age of 60. It then gradually dropped the eligibility age, eventually expanding it to everyone aged 12 and up who received the second shot at least five months ago.

As of Thursday, nearly 3 million Israelis had received their third dose.

Meanwhile in the US, influential government advisers will debate Friday if there’s enough proof that a booster dose of Pfizer’s COVID-19 vaccine is safe and effective — the first step toward deciding which Americans need one and when.

The Food and Drug Administration on Wednesday posted much of the evidence its advisory panel will consider.

Pfizer’s argument is that while protection against severe disease is holding strong in the US, immunity against milder infection wanes somewhere around six to eight months after the second dose.

More important, Pfizer said, those antibodies appear strong enough to handle the extra-contagious Delta variant that is surging around the world.

A man receives his third dose of the COVID-19 vaccine at a temporary health care center in Jerusalem, on August 29, 2021. (Yonatan Sindel/Flash90)

To bolster its case, Pfizer pointed the FDA to the new data from Israel.

Pfizer said the data published on Thursday translates to “roughly 95% effectiveness” against Delta — comparable to the protection seen shortly after the vaccine’s rollout earlier in the year.

In Israel, the R-value — the reproduction rate of the virus measuring the average number of people each positive person infects — rose to 1.14 on Thursday, after it had hit a 4-month low of 0.81 just days earlier.

Any number over 1 indicates infections are rising, while a figure below that signals that an outbreak is abating.

There were 8,601 new COVID-19 cases diagnosed on Wednesday, according to the Health Ministry.

Of the 83,704 active cases, 654 are in serious condition. Since the start of the pandemic last year, 7,465 people have died of COVID-19 complications in Israel.

Prof. Moshe Shoham (courtesy)

Robots have captured the imaginations – and often raised the fears – of people for at least a century. These programmable machines perform boring, repetitive and dangerous tasks that people prefer not to or are unable to do because of size limitations or because they function in extreme environments such as in outer space or at the bottom of the sea.

The term comes from a Slavic root, robot-, with meanings connected to the word “labor” and was first used to denote a fictional humanoid in a Czech-language play R.U.R. (Rossumovi Univerzální Roboti – Rossum’s Universal Robots) written 101 years ago by Karel Čapek, (although it was apparently Karel’s brother Josef  who first gave the concept a name).

A robot may be guided by an externally controlled device or the control may be embedded inside its body. Robots can be constructed to look like humans or even dogs, but most robots are functional machines that perform tasks efficiently and thus designed without much attention to aesthetics.

They can be programmed to function autonomously or semi-autonomously and include humanoids such as Honda’s ASIMO (Advanced Step in Innovative Mobility) – the apex of 20 years of robotics research that can run, walk on uneven slopes and surfaces, climb stairs, turn smoothly, reach for and grasp objects and even understand and respond to simple voice commands. Robots are beginning to assist in hospitals, take hotel guests to their rooms, accept and deliver food orders and carry out numerous other tasks. But more common are industrial robots that build cars and perform other manufacturing work in factories, medical operating robots, high-flying drones that observe and even attack enemies, patient-assist robots and dog therapy robots that assist and reduce loneliness among the elderly and the disabled.

The 1966 American science fiction movie Fantastic Voyage about a submarine crew who are shrunk to microscopic size and float inside the body of an injured scientist to repair damage to his brain even presaged microscopic nano robots that today are hinting that they are no longer science fiction.

One of the world’s leaders in medical robots – the founder of numerous companies, the inventor with more than 100 individual patents publisher of more than 200 technical papers and three books and the teacher who has inspired many young people in Israel and around the world to enter the field – is Emeritus Prof. Moshe Shoham, who was born in Haifa. His official title is bearer of the Tamara and Harry Handelsman Academic Chair and director of the robotic laboratory in the department of mechanical engineering at the Technion – Israel Institute of Technology
in Haifa.

In 1978, Shoham earned his bachelor of science degree from the Technion in in the Faculty of Aeronautical Engineering, worked in Israel Aerospace Industries followed four years later by a master’s degree from its Faculty of Mechanical Engineering and a doctorate in 1986 from that same faculty. His main professional interests are robotic systems (kinematics and dynamics of robots), multi-fingered hands, sensor-based robots and medical robotics.

There were no approved medical robots in the world when he began. The pioneer in this area was a company named ISS, which developed a robot for replacing the hip joint, thereby opening the market, but eventually it failed to obtain approval from the US Food and Drug Administration (FDA). The company closed down in 2005, exactly when Shoham’s company, Mazor Robotics Ltd., got its marketing approval. In 2001, he founded Mazor, which was acquired in 2018 by the global medical electronics company Medtronic for $1.64 billion.

After working in the Israel Aerospace Industries, Shoham served as an assistant professor at Columbia University in New York and established the robotic laboratory at the department of mechanical engineering, a visiting professor at Stanford University in California. He is also a Fellow of the Institute of Electrical and Electronics Engineers (IEEE) Fellow of the American Society of Mechanical Engineers (ASME) and a International Member of the US National Academy of Engineering,

Among his numerous awards, are honorary membership – Israel Society for Medical and Biological Engineering, 2020; the Maurice E. Müller Award for Excellence in Computer Assisted Surgery, 2019; Innovation Award – Surgical Robot Challenge, Imperial College, London, 2016; Fellow –Institute of Electrical and Electronics Engineers (IEEE), 2015; International Member – US National Academy of Engineering, 2014; Thomas A. Edison Patent Award – American Society of Mechanical Engineers, 2013; Hershel Rich Innovation Award, 2011; Technology Award – the Society for Medical Innovation and Technology (SMIT), 2008; Fellow – The American Society of Mechanical Engineers (ASME), 2008; Outstanding Israeli project – ROBOCAST: ROBOt and sensors integration for Computer Assisted Surgery and Therapy, European Union 7th Framework Program for Research and Technological Development. Awarded by the European Commission to the State of Israel, 2007; Kaplan Prize for Creative Management of High Technology, 2002; and the Juludan Award for Outstanding Scientific Research Achievements, 1999. Shoham is particularly proud of the recent 2021 Yigal Allon Prize for Pioneering Excellence – given annually to individuals, entities or organizations whose activity serves as a model of pioneering excellence and a significant contribution to Israeli society – that he received recently.

The 2021 prize was awarded jointly to Shoham and Start-Up Nation Central for their work in promoting Israeli innovation in industry. “The entire state of Israel walks in your path,” Israel’s President Isaac Herzog said in congratulatory remarks.

Among the most memorable and thought-provoking award for Shoham was in 1999, when he received a research award for the development of a robot that performs knee replacement surgery with great precision.

“Next to me, Prof. Gershon Golomb from the Hebrew University of Jerusalem’s Faculty of Medicine also received the award. The winners’ families were invited to the award ceremony. At the entrance to the hall, I saw and was shocked that instead of coming to me, my mother fell into the arms of the mother of Prof. Golomb whom I did not know and burst into tears. When they stopped crying, my mother told me that Golomb’s mother shared with her a wooden bunk in the Auschwitz concentration camp during the Holocaust. They encouraged and strengthened each other during all that terrible time.”

This moving event “made me wonder: how many more people could have received the prize but did not because they were murdered in the Holocaust.” Among them were potential writers, poets, musicians, scientists, rabbis, actors, geniuses, shoemakers, carpenters, tanners. “How many worlds will no longer be created, and why?!”

Indeed, if the mothers of Prof. Shoham and Prof. Golomb had (God forbid) perished in the gas chambers of Auschwitz, their sons would never had been born and their great healing and lifesaving accomplishments would have been lost to the world.

Shoham’s father was born in Romania and escaped from Europe during the Nazi era, fortunately moving to Israel, where he settled in the youth village and agricultural settlement of Mikve Yisrael and helped establish a kibbutz called Tehiya. His mother was born in Czechoslovakia, and after being liberated from the concentration camp, moved to Palestine where she met her future husband at the kibbutz.

Moshe, who recalls that his family lived in modest circumstances, liked from boyhood to build and fix things. That hobby led to his outstanding mechanical engineering career.

Today, he and his wife  live in Hoshaya, a national-religious community settlement in the Lower Galilee. The village was established in three decades ago as a Nahal settlement, originally planned for soldiers from moshavim in the Galilee and later manned by soldier of the Religious Nahal Youth Aliyah, Three years later, it was transferred to civilians, and 15 families moved into caravans on the site, with some of the original Nahal soldiers remaining.

At Stanford, Shoham began to think about developing medical robots, which were then in their infancy. “I returned to Israel and called surgeons in all the hospitals. Even though medicine is very conservative, some of them were very supportive of the idea,” he recalled in an interview. “Some were opposed to the use of robots in surgery, and a few of them said it will not work and no robot would ever replace a human surgeon.” “we would like to apply robots at those tasks in which robots excel – accuracy and accessibility – but the decision making will always remain with the surgeon.”

Shoham established Mazor Robotic company, specializing in spinal surgery. Shoham founded a number of companies, each with a robotic surgery specialty. One company that is based on technology developed in his medical robotic laboratory donated by the late Betty and Dan Kahn, is Xact robotics, which has developed a robot for precise navigating  of flexible needle within the body. This technology is suitable for a variety of types of operations requiring penetration by a narrow instrument to a precise point deep within the body, such as biopsies, injections of drugs into internal organs, ablation (precise searing of tissue within the body) and drainage from within the body.

Another company he founded, Diagnostic Robotics, aims at dramatically reducing the time spent in emergency rooms. Shoham does not discuss what this robot can do, so it is possible that it can already perform several physical examinations even before the doctor.

ForSight Robotics is developing a surgical robotic platform for eye surgery to assist ophthalmologists. Microbot Medical (a company listed on Nasdaq as MBOT) that he co-founded has developed a system that includes miniature robots for internal cleaning of an implanted medical device, including devices implanted in the brain. His Microbot ViRob, an autonomous advancing micro robot – less than one millimeter in diameter, has the ability to crawl within cavities and lumens, allowing physicians to target a disease site with amazing precision.

So far, the device has completed animal trials; in the future, the product is likely to also prove suitable for cleaning blood vessels so as prevent heart attacks and strokes.

A company based on his doctoral student Hadas Ziso’s thesis is Tamar Robotics, which is developing a surgical robot for revolutionizing brain surgery, finally giving doctors a safer, minimally invasive tool to remove tumors and blood clots and treat other life-threatening brain conditions that now require major surgery.

“We hope we will be able to let the people suffering from these conditions get back to their lives,” Shoham says. “We believe that our robotic system is additional outstanding armament in the surgeon’s hand that can be used at those instances they perform better  than a surgeon’s free hand.” The neurosurgery robot has been tested so far on rodents, removing tumors from their brains, and removing blood hemorrhages from the brains of pigs. Shoham expects it will be permitted to be used in clinical trials in two years or so.

In many cases of robot-assisted minimally-invasive surgery, instead of directly moving the instruments, the surgeon uses telemanipulation one or several robot hands to administer the surgery. A telemanipulator is a remote manipulator that allows the surgeon to perform the normal movements associated with the surgery. The robotic arms carry out those movements using end-effectors and manipulators to perform the actual surgery.

One advantage of using the computerized method is that the surgeon does not have to be present, leading to the possibility for remote surgery.

In 1985 a robot, the Unimation Puma 200, was used to orient a needle for a brain biopsy while under computerized tomography guidance during a neurological procedure.

Another surgical system in which Shoham was not involved is the da Vinci Surgical System, made by the US company Intuitive Surgical. Approved by the by the FDA in 2000, it is designed to assist doctors in surgery using a minimally invasive approach and is controlled by a surgeon from a console. The system is used to remove prostate glands and increasingly for cardiac valve repair and hysterectomies. It was called “da Vinci” partly because  15th-century Italian genius Leonardo da Vinci’s “Study of Human Anatomy eventually led to the design of this first-known surgical robot.

“Da Vinci works as a telemanipulation, just following what surgeon does,” noted Shoham, “but we are involved in developing robots that are not telemanipulators but have higher sense of autonomy. not just following the surgeon’s hand motion,” said Shoham. “The robot will not be just a remote manipulator, but it will proceed to be fully autonomous. There are only two companies in world approved FDA to be autonomous, and this type is more of a challenge than semi-autonomous ones.”

He is very proud that many of his students have become chief executive officers or other senior developers in other companies involving medical robots. Israelis are world leaders in medical robots, thanks to the Technion professor.

As for the concern among some people that robots will put them out of a job, Shoham stresses that they will replace low-paying, tedious jobs but create many new positions.

Just as a few decades ago, they didn’t dream that everybody would carry a mobile phone around with them instead of being dependent on a land line.

On a larger scale, the initial steps for personal robots are already being sold in the form of Siri, a virtual assistant that is part of Apple Inc.’s  operating systems. The assistant uses voice queries, gesture-based control, focus-tracking and a natural-language user interface to answer questions, make recommendations and perform actions by delegating requests to a set of Internet services. The software adapts to users’ individual language usages, searches and preferences, with continuing use.

People will soon get used to the idea that everybody will have his or her own personal robot, Shoham concludes, and they will be better off. Unwilling to predict exactly where robotics will be in a decade or two, he ventured: “They definitely will be a substantial part of our lives. Combining robots with artificial intelligence and machine learning equips humanity with a strong new power. I hope it will be used wisely.”

Researchers at the Technion have developed a highly stretchable electronic material and a wearable sensor capable of identifying precise bending and twisting motions.

Scientists at the Technion-Israel Institute of Technology have produced a highly stretchable electronic material and a wearable sensor capable of identifying precise bending and twisting motions.

Essentially, it is an electronic skin.

The development will be able to help identify ailments and disease, for example, the early onset of Parkinson’s, or help amputees adapt to prosthetics, the developers have said.

It recognizes the range of movements that human joints normally makes with the precision of up to half a degree. This breakthrough is the result of collaborative work, headed by Professor Hossam Haick from the Wolfson Faculty of Chemical Engineering.

It was recently published in Advanced Materials, a peer-reviewed journal. 

Professor Haick’s lab focuses on wearable devices. Wearable motion sensors can currently recognize bending movement, but not twisting. Sensors that recognize twisting are large and cumbersome.

Ph.D candidate Yehu David Horev and postdoctoral fellow Dr. Arnab Maity have found a way to overcome this problem. Horev found a way to form a composite material that is both usable as a sensor and is flexible, stretchable, breathable, biocompatible, and does not change its electrical properties when stretched.

Dr. Maity was able to solve the mathematics of analysing the received signal.

Professor Hossam Haick (credit: TECHNION SPOKESPERSON’S OFFICE)

The novel sensor is breathable, durable and lightweight, allowing it to be worn by humans for long periods of time. 

“This sensor has many possible applications,” Prof. Haick stated. 

“It can be used in early disease diagnosis, alerting of breathing alterations, and motor system disorders such as Parkinson’s disease. It can be used to assist patients’ motor recovery and be integrated into prosthetic limbs. In robotics, the feedback it provides is crucial for precise motion. In industrial uses, such sensors are necessary in monitoring systems.”

TECHNION SCIENTISTS CREATED A WEARABLE MOTION SENSOR CAPABLE OF IDENTIFYING BENDING AND TWISTING

One doesn’t pay much attention to sensors, but they are omnipresent in modern life. A sensor is a device that responds to a physical stimulus such as heat, light, sound, pressure, magnetism or a particular motion and transmits a resulting impulse as for measurement or operating a control. It measures physical input from its environment and converts it into data that can be interpreted by either a human or a machine.

The most frequently used types of sensors are classified according to hat they react to – electric current or magnetic or radio sensors, humidity, fluid velocity or flow, pressure, temperature sensors, proximity sensors, optical sensors or position sensors.

Sensors are used in everyday objects such as touch-sensitive elevator buttons, lamps that brighten or dim by touching the base, along with innumerable applications of which most people are unaware. 

Aside from home use, sensor applications include manufacturing, medicine, machinery, planes and aerospace, vehicles, robotics and many other aspects of life. 

Wearable strain sensors have been attracting special attention in the detection of human posture and activity, as well as for the assessment of physical rehabilitation and kinematic, but it is a challenge to fabricate stretchable and comfortable-to-wear permeable strain sensors that can provide highly accurate and continuous motion recording while exerting minimal constraints and maintaining low interference with the body. 

Now, scientists at the Technion-Israel Institute of Technology in Haifa have created a wearable motion sensor capable of identifying bending and twisting. Made from a highly stretchable electronic material, it is essentially an electronic skin capable of recognizing the range of movement human joints normally make, with up to half a degree precision. 

This breakthrough is the result of collaborative work among researchers from different fields in the Laboratory for Nanomaterial-Based Devices, headed by Prof. Hossam Haick from the Wolfson Faculty of Chemical Engineering. It was recently published in Advanced Materials under the title “Stretchable and Highly Permeable Nanofibrous Sensors for Detecting Complex Human Body Motion”

and was featured on the journal’s cover.

The new sensor has many possible applications,” said Haick. “It can be used in early disease diagnosis, alerting of breathing alterations, and motor system disorders such as Parkinson’s disease. It can also assist patients in their motor recovery and be integrated into prosthetic limbs. In robotics, the feedback it provides is crucial for precise motion. In industrial uses, such sensors are necessary in monitoring systems, putting them at the core of the Fourth Industrial Revolution.”

This breakthrough is the result of collaborative work between researchers from different fields in the Laboratory for Nanomaterial-Based Devices, which Haick heads. 


At present, existing wearable motion sensors can recognize bending movement, but not twisting. Existing twisting sensors, on the other hand, are large and cumbersome and cannot be worn.. This problem was overcome by doctoral candidate Yehu David Horev and postdoctoral fellow Dr. Arnab Maity. 

Horev found a way to form a composite material that was both conductive – and thus, usable as a sensor – and flexible, stretchable, breathable and biocompatible, I also did not change its electrical properties when stretched. 

Maity then solved the mathematics of analyzing the received signal, creating an algorithm capable of mapping bending and twisting motion – the nature of the movement, its speed and its angle. The novel sensor is breathable, durable and lightweight, making it possible to be worn on the human body for prolonged periods.

“Electrically conductive polymers are usually quite brittle,” explained Yehu about the challenge the group had overcome. “To solve this, we created a composite material that is a little like fabric. The individual polymer ‘threads’ cannot withstand the strain on the material, but their movement relative to each other lets it stretch without breaking. It is not too different from what lends stretch to T-shirts. This allows the conductive polymer withstand extreme mechanical conditions without losing its electrical properties.”

What makes this achievement more important is that the materials the group used are very inexpensive, resulting in a cheap sensor. “If we make a device that is very expensive, only a small number of institutions in the Western world could afford to use it. We want the technological advances we achieve to benefit everyone, regardless of their geographic location and socioeconomic status,” said Haick. True to his word, among the laboratory’s other projects is a tuberculosis-diagnosing sticker patch, which is sorely needed in developing countries.

Haick is an expert in the field of nanotechnology and non-invasive disease diagnosis who earned his doctorate from the Technion in 2002. After graduation, he completed two postdoctoral fellowships – first at the Weizmann Institute of Science in Rehovot and then at California Institute of Technology. He returned to the Technion at the end of 2006 as an assistant professor, becoming a full professor in 2011. 

He has published more than 220 publications in top-level journals in the field of nanotechnology, advanced/applied materials/chemistry and medicine, and technologies he and his team developed have led to the production of more than 42 patents and patent applications – many of which have been licensed to six international companies.

An Arab-Israeli scientist and engineer, Haick is a pioneer known for inventing the Nano Artificial Nose for detection of disease from exhaled breath.  He was included in more than 80 top-rank listings worldwide, including the “MIT Technology Review” list of 35 leading young scientists in the world, the “50 Sharpest Israeli Minds” and  the world’s top-100 influential innovators in the Digital Technology by Nominet Trust in London. 

A team of scientists has found why elderly people are more susceptible to COVID-19 and are working to reverse the aging process of the body’s immune system

Scientists from the Technion-Israel Institute of Technology say they have found a way to rejuvenate the aging process of the body’s immune system.

Prof. Doron Melamed and doctoral student Reem Dowery sought to understand why the elderly population is more susceptible to severe cases of COVID-19 and why the vaccines seem to be less effective and wane faster among this population.

The results of their work were published this month in the peer-reviewed, online medical journal Blood.

The secret begins with B cells, also known as B lymphocytes. These are the cells that produce antibodies against any pathogen that enters the body. They play a key role in protecting people from viruses and diseases.

B cells are produced in bone marrow and then travel through the blood to lymph nodes and the spleen, where they wait for pathogens to enter and then attack them.

“When you are young, you have young cells, and young cells have a very diverse ability to recognize anything [pathogenic] that comes into your body,” Melamed told The Jerusalem Post.

B cells do not live long, but they are constantly being replenished by new ones sent from the bone marrow, creating what Melamed calls “homeostasis,” a state in which the total number of B cells in the bone marrow and outside remains constant.

However, B cells do not just disappear. They turn into “memory” B cells so that if the body is exposed to a previous pathogen, the individual will not get sick. That is because the immune response will be fast and robust, and it will eliminate the pathogen, often without the individual knowing he or she had been exposed to it.

Unlike B cells, memory cells are long-lived.

“Imagine you are growing into adulthood, and you become an adult and then an older person,” Melamed said. “You accumulate in your body many memory cells. You are exposed all the time to pathogens, and hence you make more and more memory cells. Because these are so long-lived, there is no room left for new B cells.

”What happens when a new pathogen, such as the coronavirus, comes along? There are no young B cells that can recognize it.

That is one of the reasons why older people are more susceptible to severe COVID-19 and many other diseases.

As noted, this happens because of the body’s need for homeostasis, something that Melamed’s lab discovered a decade ago.

BUT THIS year, they took the discovery another step and figured out a mechanism to override the system.

“We found specific hormonal signals produced by the old B cells, the memory cells, that inhibit the bone marrow from producing new B cells,” Melamed said. “This is a huge discovery. It is like finding a needle in a haystack.

”It also means that, over time, specific drugs or treatments can be found to inhibit one of the hormones in the signaling pathway and get the bone marrow to produce new B cells.

Melamed Research group (credit: NITZAN ZOHAR/TECHNION SPOKESPERSON’S OFFICE)

What happens when a new pathogen, such as the coronavirus, comes along? There are no young B cells that can recognize it

.That is one of the reasons why older people are more susceptible to severe COVID-19 and many other diseases.

As noted, this happens because of the body’s need for homeostasis, something that Melamed’s lab discovered a decade ago.

BUT THIS year, they took the discovery another step and figured out a mechanism to override the system.
“We found specific hormonal signals produced by the old B cells, the memory cells, that inhibit the bone marrow from producing new B cells,” Melamed said. “This is a huge discovery. It is like finding a needle in a haystack.

”It also means that, over time, specific drugs or treatments can be found to inhibit one of the hormones in the signaling pathway and get the bone marrow to produce new B cells.

To validate their theory, Melamed’s lab collaborated with the departments of hematology and rheumatology at Sourasky Medical Center in Tel Aviv and Rambam Health Care Campus in Haifa. As part of treatment for some medical conditions, such as lupus, lymphoma and multiple sclerosis, patients undergo B cell depletion, meaning a significant amount of memory B cells is removed from their bodies.

Examining older patients who underwent this procedure, the group found that their immune systems rejuvenated, and their bodies could produce new B cells again.

An effect similar to B cell depletion can be produced by inhibiting one of the hormones in the signaling pathway that suppresses the production of new B cells.

“Now we understand that there is some kind of conversation between compartments in the body, between how B cells are produced and what controls that,” Melamed said.

In the interim, he recommended that doctors use this knowledge to protect the elderly better, such as by instituting a vaccination program targeted just for the adult population that preempts variants with an additional shot.

“Even every three or four months, vaccinate them again and again to ensure they maintain high antibodies,” Melamed said.

He also suggested mixing vaccines, such as combining a shot of a Pfizer mRNA vaccine with an AstraZeneca booster given several months later, “which may generate better stimulation of the elderly immune system.

”At the same time, clinical trials would be needed to determine how to safely inhibit the hormones to find a longer-term solution, hopefully before the next pandemic, Melamed said.

Overall effectiveness of coronavirus vaccines has not dropped much yet for most vaccinated Americans, US Centers for Disease Control and Prevention vaccine advisers were told Monday.

CDC’s Advisory Committee on Immunization Practices met Monday to discuss the potential eventual need for booster doses of coronavirus vaccine — although they did not vote. The White House has said it’s planning to offer booster doses at the end of September, although it’s up to the US Food and Drug Administration and the CDC to decide on this.

So far, in data that goes through July, the vaccines still appear to provide strong protection, the CDC’s Dr. Sara Oliver told ACIP Monday.

“Since the introduction of the Delta variant, VE against infection ranges from 39 to 84%. VE against hospitalization, though, remains high from 75% to 95%,” Oliver said, citing global data.

“Regardless of the vaccine evaluated, all vaccines remain effective in preventing hospitalization and severe disease. But they may be less effective in preventing infection and mild illness recently,” Oliver added. “These reasons for lower effectiveness likely include both waning over time and the Delta variant.”

One US study showed vaccine effectiveness against hospitalization in adults 65 and older may have decreased, but only slightly, over time, she said. Unpublished CDC data shows vaccine effectiveness remains very high, at 94% or higher in adults 18 to 74, she said.

“Preliminary VE against hospitalization in adults 75 years of age and older … decreased in July but still remained over 80%,” Oliver said.

Vaccine efficacy has fallen from 75% at first to just over 50% among long term care facility residents, Oliver said. These were the first people vaccinated after the shots became available in December and January.”

The data we have seen today has demonstrated that Covid vaccines continue to maintain high protection against severe disease, hospitalization and death. Protection against infection, including asymptomatic and mild infection, appears to be lower in recent months,” she said.

All three companies making vaccines for the US market — Pfizer/BioNTech, Moderna and Johnson & Johnson — are evaluating the effects of booster doses, she said.

The major questions are whether booster doses are safe and work to improve protection, she said.

“Will booster doses of Covid-19 vaccines reduce Covid-19 incidence, hospitalization and/or mortality?” she asked.

ACIP will meet in the coming weeks to discuss data about vaccine efficacy in August, Oliver said. “We will announce meetings as soon as we have dates,” the CDC’s Dr. Amanda Cohn said at the end of Monday’s meeting.

The CDC and FDA endorsed the use of boosters in certain immunocompromised people earlier this month. While the White House has pressed for booster doses to be offered more widely, the CDC and FDA are waiting for more information from the companies.

But White House officials say they’re looking at data from Israel as well as from the US, and want to be sure to be ahead of any changes in the pandemic.

On Monday, Israel started offering a booster to everyone 12 and older who had been vaccinated at least five months ago.

Researchers in Israel reported Monday that people who chose to get a third dose of vaccine had a much lower risk of becoming infected, even as the more transmissible Delta variant swept across the country.

“Conclusions: In conjunction with safety reports, this study demonstrates the effectiveness of a third vaccine dose in both reducing transmission and severe disease and indicates the great potential of curtailing the Delta variant resurgence by administering booster shots,” Yair Goldberg of the Technion-Israel Institute of Technology and colleagues wrote in their report, posted online by the Israeli government.

The researchers noted that it is difficult to account for differences among people in a real-world study. People who choose to get a booster dose may be different from those who choose not to, and people behave differently after they’ve received a shot.

One major difference: recently vaccinated people are less likely to be tested for coronavirus infection, which means fewer infections would be detected in that group. Recently vaccinated people may also take more care to prevent infection.